CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Exclusion Criteria

• •1. Have a history of allergy to any component of cell products;
• •2. There are clinically significant cardiovascular diseases, such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or any grade 3 (moderate) or grade 4 (severe) heart disease with cardiac function (according to the functional classification method of the New York Heart AssociationNYHA) with a history of myocardial infarction, angioplasty or stent implantation, unstable angina or other clinically significant heart disease within 12 months before admission;
• •3. who has suffered from brain injury, consciousness disorder, epilepsy, more serious cerebral ischemia or cerebral hemorrhage disease;
• •4. Patients who need urgent treatment due to tumor progression or spinal cord compression;
• •5. The investigator determines that there are serious complications or diseases that will increase the risk of the subject or affect the study, including but not limited to, for example, cirrhosis, recent major trauma, etc;
• •6. After allogeneic hematopoietic stem cell transplantation;
• •7. Patients with autoimmune diseases, immunodeficiency or other diseases requiring immunosuppressive（excluding glucocorticoid）therapy;
• •8. There was uncontrolled active infection;
• •9. There were live vaccinations within 4 weeks before admission;
• •10. Active hepatitis (positive for HBVDNA or HCVRNA), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to those with HIV infection;
• •11. Subjects had a history of alcohol, drug or mental illness;
• •12. The researchers believe that there are other conditions that subjects are not suitable to participate in this study.